Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6

Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature

Authors Daniel J Abrams, Donald C Rojas, David B Arciniegas

Published 5 December 2008 Volume 2008:4(6) Pages 1089—1109


Review by Single-blind

Peer reviewer comments 2

Daniel J Abrams1, Donald C Rojas1, David B Arciniegas1,2

1Department of Psychiatry; 2Neurobehavioral Disorders Program, Departments of Psychiatry and Neurology, University of Colorado School of Medicine, Denver, CO, USA

Abstract: Considerable debate surrounds the inclusion of schizoaffective disorder in psychiatric nosology. Schizoaffective disorder may be a variant of schizophrenia in which mood symptoms are unusually prominent but not unusual in type. This condition may instead reflect a severe form of either major depressive or bipolar disorder in which episode-related psychotic symptoms fail to remit completely between mood episodes. Alternatively, schizoaffective disorder may reflect the co-occurrence of two relatively common psychiatric illnesses, schizophrenia and a mood disorder (major depressive or bipolar disorder). Each of these formulations of schizoaffective disorder presents nosological challenges because the signs and symptoms of this condition cross conventional categorical diagnostic boundaries between psychotic disorders and mood disorders. The study, evaluation, and treatment of persons presently diagnosed with schizoaffective may be more usefully informed by a dimensional approach. It is in this context that this article reviews and contrasts the categorical and dimensional approaches to its description, neurobiology, and treatment. Based on this review, an argument for the study and treatment of this condition using a dimensional approach is offered.

Keywords: schizoaffective disorder, schizophrenia, bipolar disorder, manic-depressive disorder

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Outcomes of microincision vitrectomy surgery with internal limiting membrane peeling for macular edema secondary to branch retinal vein occlusion

Sato S, Inoue M, Yamane S, Arakawa A, Mori M, Kadonosono K

Clinical Ophthalmology 2015, 9:439-444

Published Date: 4 March 2015

Clinical and pathological implications of miRNA in bladder cancer

Braicu C, Cojocneanu-Petric R, Chira S, Truta A, Floares A, Petrut B, Achimas-Cadariu P, Berindan-Neagoe I

International Journal of Nanomedicine 2015, 10:791-800

Published Date: 20 January 2015

Antibacterial activity and cytotoxicity of multi-walled carbon nanotubes decorated with silver nanoparticles

Seo Y, Hwang J, Kim J, Jeong Y, Hwang MP, Choi J

International Journal of Nanomedicine 2014, 9:4621-4629

Published Date: 30 September 2014

Manganese-containing Prussian blue nanoparticles for imaging of pediatric brain tumors

Dumont MF, Yadavilli S, Sze RW, Nazarian J, Fernandes R

International Journal of Nanomedicine 2014, 9:2581-2595

Published Date: 23 May 2014

Effects of titania nanotubes with or without bovine serum albumin loaded on human gingival fibroblasts

Liu X, Zhou X, Li S, Lai R, Zhou Z, Zhang Y, Zhou L

International Journal of Nanomedicine 2014, 9:1185-1198

Published Date: 6 March 2014

Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients

Maruyama K, Tsuchisaka A, Sakamoto J, Shirato S, Goto H

Clinical Ophthalmology 2013, 7:1441-1446

Published Date: 15 July 2013

Natural material adsorbed onto a polymer to enhance immune function

Reinaque AP, França EL, Scherer EF, Côrtes MA, Souto FJ, Honorio-França AC

Drug Design, Development and Therapy 2012, 6:209-216

Published Date: 27 August 2012

Update on the management of neuromuscular block: focus on sugammadex

Hans D de Boer, Jan van Egmond, Jacques J Driessen, Leo HD Booij

Neuropsychiatric Disease and Treatment 2007, 3:539-544

Published Date: 15 November 2007

Mood fluctuations in Parkinson’s disease: a pilot study comparing the effects of intravenous and oral levodopa administration

Irene Hegeman Richard, Samuel Frank, Kori A LaDonna, Hongkun Wang, Michael P McDermott, Roger Kurlan

Neuropsychiatric Disease and Treatment 2005, 1:261-268

Published Date: 15 October 2005

Letter - Possible deleterious effects of adjunctive omega-3 fatty acids in post-traumatic stress disoder patients

Kaplan Zeev, Matar Michael, Kamin Ram, Cohen Hagit

Neuropsychiatric Disease and Treatment 2005, 1:187-188

Published Date: 15 July 2005